electroCore, Inc.

electroCore, Inc. develops and commercializes non-invasive bioelectronic therapies based on vagus nerve stimulation. Its core products include prescription gammaCore devices for headache and related indications, along with wellness-oriented handheld devices sold in the United States, the United Kingdom, and selected international markets.

−39,5 %

86,8 %

−43,6 %

+27,2 %

1.38

1.24

— electroCore, Inc.
%
Prescription gammaCore therapy75% Non-invasive vagus nerve stimulation devices sold for prescribed use, especially in government and UK healthcare channels.
Direct-to-consumer wellness devices17% Truvaga handheld products marketed for general wellness and sold through consumer channels and e-commerce.
TAC-STIM wellness devices1% Consumer-oriented handheld devices positioned for wellness and human performance use.
International distribution7% Sales of nVNS products outside the United States and the United Kingdom through distribution partners.

The company sells primarily to federal healthcare systems in the United States and to the UK National Health Service,...

  • U.S. federal healthcare systemsprimary

    VA, DoD, MHS and IHS facilities buy gammaCore for covered patients through federal procurement channels.

  • UK National Health Serviceprimary

    NHS buyers use prescription gammaCore under funding and catalog arrangements for cluster headache treatment.

  • Direct-to-consumer wellness buyerssecondary

    Consumers purchase Truvaga and TAC-STIM for general wellness and human performance use.

  • International distribution partnerssecondary

    Partners buy or distribute nVNS products in selected territories outside the U.S. and UK.

The company’s commercial footprint is centered in the United States and the United Kingdom, with the U.S...

  • •United States is the main market, especially the federal healthcare channel
  • •United Kingdom is a core market through NHS and MTFM arrangements
  • •Selected non-U.S. territories are served through distribution partners
  • •Government procurement portals shape U.S. channel access and timing
  • •Country-specific reimbursement and guidance affect adoption and pricing

electroCore is focused on expanding prescription gammaCore within federal healthcare and the UK public system while...

01
Expand federal channel salesshort-term

The VA and related federal systems are the largest revenue source and provide repeat procurement access.

02
Protect and extend UK reimbursement accessshort-term

NHS listing and funding support are important for prescription gammaCore adoption in the UK.

03
Grow wellness and direct-to-consumer productsmedium-term

Consumer products diversify revenue beyond prescription reimbursement and government procurement.

04
Broaden international distributionmedium-term

Selected territories outside the U.S. and UK can extend the platform without building full direct sales coverage.

The business depends heavily on a small number of government and public healthcare buyers, so procurement changes,...

high

Customer concentration in federal and UK public healthcare channels

A large share of revenue comes from a few buyers and procurement systems, so contract or policy changes can quickly affect sales.

Scope
VA, DoD, NHS
Materiality
high
high

Reimbursement and guidance risk in the UK

NICE or NHS changes could alter access, pricing, or funding for gammaCore under the MTFM program.

Scope
United Kingdom
Materiality
high
high

Financing and covenant constraints

The company has recurring losses and debt arrangements can restrict operating flexibility and asset use.

Scope
Loan and Security Agreement with Avenue
Materiality
high
medium

E-commerce marketplace dependency

Truvaga sales rely on online marketplaces that can suspend listings or classify products as regulated medical devices.

Scope
Direct-to-consumer channels
Materiality
medium
Revenue recognition by channel
Quarterly revenue comparability
Estimated useful lives of licensed devices
Gross margin and depreciation/amortization
Inventory valuation
Cost of goods sold and working capital
Debt and covenant accounting
Liquidity presentation and going-concern assessment

VYCOR MEDICAL INC

VYCO · Surgical & Medical Instruments & Apparatus

Electromed, Inc.

ELMD · Electromedical & Electrotherapeutic Apparatus

NovoCure Ltd

NVCR · Surgical & Medical Instruments & Apparatus

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Inspire Medical Systems, Inc.

INSP · Surgical & Medical Instruments & Apparatus

TACTILE SYSTEMS TECHNOLOGY INC

TCMD · Surgical & Medical Instruments & Apparatus

: 29/04/2026